Washington, District of Columbia 20307

  • Cervical Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or recurrent cancer of the cervix.

Study summary:

OBJECTIVES: - Determine the antitumor activity of gemcitabine in patients with persistent or recurrent nonsquamous cell carcinoma of the cervix who failed higher priority treatment protocols. - Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive gemcitabine IV over 30 minutes weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 15-37 patients will be accrued for this study within 1 year.


DISEASE CHARACTERISTICS: - Diagnosis of persistent or recurrent nonsquamous cell carcinoma of the cervix that has failed local therapeutic measures and is considered incurable - Eligible subtypes: - Adenocarcinoma - Adenosquamous carcinoma - Undifferentiated carcinoma - Must have documented disease progression - Histologic confirmation of original primary tumor required - Bidimensionally measurable disease - Ineligible for higher priority GOG protocol PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - GOG 0-2 Life expectancy: - Not specified Hematopoietic: - Platelet count at least 100,000/mm^3 - Granulocyte count at least 1,500/mm^3 Hepatic: - Bilirubin no greater than 1.5 times normal - SGOT and alkaline phosphatase no greater than 3 times normal Renal: - Creatinine no greater than 1.5 mg/dL Other: - No significant infection - Not pregnant - Fertile patients must use effective contraception - No other invasive malignancy within the past 5 years except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent filgrastim (G-CSF) Chemotherapy: - No prior gemcitabine - At least 3 weeks since other prior chemotherapy for cervical cancer and recovered - No more than 1 prior chemotherapy regimen (single or combination cytotoxic therapy) Endocrine therapy: - Not specified Radiotherapy: - At least 3 weeks since prior radiotherapy for cervical cancer and recovered Surgery: - At least 3 weeks since prior surgery for cervical cancer and recovered Other: - No prior cancer treatment that would preclude study

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Official Title:

Evaluation of Gemcitabine in Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Gynecologic Oncology Group

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Russell J. Schilder, MD
Study Chair
Fox Chase Cancer Center

Study Dates

Start Date:September 2000
Primary Completion Date:April 2005
Primary Completion Type:Actual
Verification Date:June 2005
Last Changed Date:April 10, 2013
First Received Date:September 11, 2000

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:gemcitabine hydrochloride

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Gynecologic Oncology Group
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005 Jan;96(1):103-7.

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.